Tafasitamab, an anti-CD19 immunotherapy, is used with lenalidomide for patients with autologous stem cell transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma based on the results of the phase II L-MIND study (NCT02399085).
Roche and Polyphor Ltd., a privately held pharmaceutical company, announced that they have entered into an exclusive worldwide license agreement...
Biotronik has received FDA approval of its new Lumax 740 implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy devices (CRT-Ds)....
United Therapeutics Corporation announced that the BEAT clinical study of esuberaprost tablets in patients suffering from pulmonary arterial hypertension did...
Procoralan (ivabradine) from Servier Labs has been recommended by NICE in draft guidance as a treatment option for people with...
The FDA approved the first generic versions of Strattera (atomoxetine) from Eli Lilly to treat attention-deficit/hyperactivity disorder (ADHD) in pediatric...